Roche studies boost in Tamiflu dose, duration

Roche is exploring another way to boost Tamiflu sales. The company says it's starting clinical trials to test whether the antiviral is more effective if taken at higher doses and for twice as long as the current five-day course. Longer treatment, of course, means more pills--and more revenue.

Already, second-quarter sales of the drug are expected to be much higher than first-quarter numbers because of the swine flu pandemic, the Financial Times reports. If its new research pays off, and the pandemic ramps up in the Northern Hemisphere this fall as predicted, the drug could see an even bigger surge in orders.

Production is in high gear as Roche resumes selling Tamiflu to companies and private clients, rather than restricting itself to government customers. The company had reserved new supplies for government pandemic orders. And Roche recently set up a Tamiflu-buying program designed for poorer countries, under which the drug will be available at lower cost and on deferred payment terms.

- read the FT story

ALSO: Genentech, which was bought by majority shareholder Roche for $46 billion in March, won a judge's approval to settle a lawsuit contending the stock was undervalued in the deal. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.